# Glucosamine Sulfate 2KCl - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Large human prospective cohort studies (UK Biobank n=466,003) show 15% lower all-cause mortality in regular glucosamine users.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **80/100**
- **Evidence Quality Tier**: **bronze**
- **Human Clinical Evidence Strength**: 72/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 84/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Glycosaminoglycan matrix synthesis & AMPK-dependent autophagy mimetic

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 1,500 mg
- **Recommended Timing**: Dinner with food
- **Administration Type**: supplement
- **Recommended Biomarkers to Monitor**: joint_comfort, cellular_longevity

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: Severe shellfish allergy (use corn-derived fermentation version)
- **Safety Profile**: High - Well-tolerated long-term nutrient.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Long-Term Effects of Glucosamine Sulfate on Osteoarthritis Progression** [PMID: 11214126]
   - Link: https://pubmed.ncbi.nlm.nih.gov/11214126/
2. **Glucosamine Use and All-Cause Mortality: Prospective Cohort Study** [PMID: 31109964]
   - Link: https://pubmed.ncbi.nlm.nih.gov/31109964/
3. **Association of Regular Glucosamine Use with Risk of Cardiovascular Disease in Prospective Cohort (UK Biobank)** [PMID: 31182490]
   - Link: https://pubmed.ncbi.nlm.nih.gov/31182490/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Glucosamine Sulfate 2KCl on LongevityReviews](https://longevityreviews.org/modalities/glucosamine-sulfate)
- **Last Evidence Calibration**: 2026-08-09
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.